Achieve Life Sciences (ACHV) Given Daily Media Impact Rating of 0.11

Media headlines about Achieve Life Sciences (NASDAQ:ACHV) have trended somewhat positive this week, Accern reports. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Achieve Life Sciences earned a news impact score of 0.11 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.7985804084285 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of NASDAQ ACHV traded down $1.69 during midday trading on Thursday, hitting $5.26. 4,542 shares of the company’s stock were exchanged, compared to its average volume of 29,201. Achieve Life Sciences has a twelve month low of $6.77 and a twelve month high of $62.70.

Achieve Life Sciences (NASDAQ:ACHV) last issued its quarterly earnings data on Wednesday, May 9th. The biopharmaceutical company reported ($2.40) earnings per share (EPS) for the quarter.

Separately, ValuEngine upgraded Achieve Life Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms.

Insider Buying and Selling by Quarter for Achieve Life Sciences (NASDAQ:ACHV)

Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply